11th Annual Hematology and Medical Oncology Board Review: Contemporary Practice - On Demand

Friday, March 24, 2023, 9:00 AM - Wednesday, January 31, 2024, 1:00 PM

Recorded over 3.5 days, this on demand includes an up-to-date and comprehensive review of the diagnosis, staging, and management of neoplastic disease, including solid tumor and hematologic oncology. Lectures provided by expert faculty from Memorial Sloan Kettering focus on disease-specific topics in gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, and central nervous system oncology, as well as hematologic oncology.

"This is an excellent conference and not just for the boards. I take it every 2-3 years as a refresher and to see what is coming down the pipeline."

"World-class speakers!"

"Delving into each subspecialty of oncology is important as we ... care for oncologic patients outside of .. our focused daily practice."

-Attendee Feedback

This on demand course contains 35+ recorded lectures along with PDF versions of the speakers' slides. Select the 'Register' tab at the top of this page to purchase this program. Once you have successfully registered, access to the course materials will be available under the 'Course Content' tab.

1. Define state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers and hematologic cancers.
2. Discuss recent treatment advances in solid tumor and hematologic oncology and apply knowledge gained in modern clinical practice
3. Prepare for ABIM examinations in medical oncology and hematology.

On Demand Access Fees

• Physicians (MDs, PhDs, and DOs): $1,650
• Residents, Fellows, Nurses, and Other Healthcare Providers: $1,075
• Industry Professionals: $2,885
• MSK Employees: Complimentary

A 30% registration discount is available for MSK Alumni and MSK Cancer Alliance members to attend a MSK CME course. If you are a member of one of these groups, please contact [email protected] for details. Please note that after your payment has been processed, no further promotional discount adjustments will be made to your registration.

This MSK CME on demand program is non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 30.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Recorded/Review Date: March 10-13, 2023; Original Release Date: March 24, 2023; Termination Date: November 30, 2023 

MSK Course Directors 

David H. Ilson, MD, PhD, FACP, FASCO
Attending Physician, Member, Gastrointestinal Oncology Service
Professor of Medicine, Weill Cornell Medical College

Paul A. Hamlin, MD
Medical Director, David H. Koch Center for Cancer Care
Associate Attending, Lymphoma Service 
Associate Professor of Medicine, Weill Cornell Medical College

 

MSK Course Faculty

Ghassan K. Abou-Alfa, MD, MBA
Attending Physician, Gastrointestinal Oncology Service

Carol Aghajanian, MD
Attending Physician, Chief, Gynecologic Medical Oncology Service

Lior Z. Braunstein, MD
Assistant Attending Radiation Oncologist, External Beam Radiotherapy Service

Andrea Cercek, MD
Section Head, Colorectal Cancer; 
Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers; 
Associate Attending Physician, Gastrointestinal Oncology Service

Paul B. Chapman, MD
Attending Physician, Melanoma Service

Noura J. Choudhury, MD
Assistant Attending Physician, Thoracic Oncology Service & Early Drug Development Service

Hiram S. Cody III, MD, FACS
Attending Surgeon, Breast Service;
Professor of Surgery, Weill Cornell Medical College

Chau T. Dang, MD
Regional Care Network Medical Site Director, MSK Westchester;
Attending Physician, Breast Medicine Service

Mark A. Dickson, MD
Associate Attending Physician, Sarcoma Medical Oncology Service

Lara A. Dunn, MD
Assistant Attending Physician, Head and Neck Oncology Service

Darren R. Feldman, MD
Chair, Quality Assurance;
Section Head, Germ Cell Cancer;
Associate Attending Physician, Genitourinary Oncology Service; 
Associate Professor of Medicine, Weill Cornell Medical College

Devika Gajiria, MD
Assistant Attending Physician, Breast Medicine Service

Mark B. Geyer, MD
Adolescent and Young Adult Program Leader;
Assistant Attending, Leukemia Service & Cellular Therapy Service;
Assistant Professor of Medicine, Weill Cornell Medicine

Mrinal M. Gounder, MD
Associate Attending Physician, Sarcoma Medical Oncology & Early Drug Development (Phase I);
Physician Ambassador, India and Asia, Bobst International Center, MSK

Rachel N. Grisham, MD
Section Head, Ovarian Cancer;
Director, Gynecologic Medical Oncology, MSK Westchester;
Associate Attending Physician, Gynecologic Medical Oncology Service

Malin Hultcrantz, MD
Assistant Attending Physician, Myeloma Service;
Assistant Professor of Medicine, Weill Cornell Medicine

Gopa Iyer, MD
Section Head, Bladder Cancer;
Associate Attending Physician, Genitourinary Oncology Service & Early Drug Development Service 

Thomas J. Kaley, MD
Vice Chair, Department of Neurology; 
Associate Attending Neuro-Oncologist

Simon Mantha, MD, MPH
Attending Physician, Hematology Service

Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program;
Attending Physician, Leukemia Service

Jodi V. Mones, MD
Associate Fellowship Program Director;
Associate Attending Physician, Hematology Service

Alison J. Moskowitz, MD
Associate Attending Physician, Lymphoma Service

Robert J. Motzer, MD
Section Head, Kidney Cancer;
Jack and Dorothy Byrne Chair in Clinical Oncology;
Attending Physician, Genitourinary Oncology Service

Eileen M. O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology;
Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research;
Section Head, Hepatopancreaticobilary & Neuroendocrine Cancers;
Attending Physician, Member, Gastrointestinal Oncology Service;
Professor of Medicine, Weill Cornell Medical College

Rekha Parameswaran, MD
Attending Physician, Hematology Service

Gregory J. Riely, MD, PhD
Vice Chair, Clinical Research; 
Attending Physician, Thoracic Oncology Service 

Lindsey Roeker, MD
Assistant Attending Physician, Leukemia Service

Leonard Saltz, MD
Executive Director for Clinical Value & Sustainability;
Head, Colorectal Oncology Section;
Attending Physician, Gastrointestinal Oncology Service;
Professor of Medicine, Weill Cornell Medical Center

Rachel Sanford, MD
Assistant Attending Physician, Breast Medicine Service

Michael Scordo, MD
Assistant Attending Physician, Bone Marrow Transplant Service & Cellular Therapy Service

Susan K. Seo, MD
Director, Antibiotic Management Program; 
Attending Physician, Infectious Disease Service 

Gunjan L. Shah, MD
Assistant Attending Physician, Bone Marrow Transplant Service & Cellular Therapy Service

Susan F. Slovin, MD, PhD
Associate Vice Chair, Academic Affairs;
Attending Physician, Genitourinary Oncology Service & Cellular Therapy Service

Zsofia K. Stadler, MD
Clinical Director, Clinical Genetics Service;
Associate Attending Physician, Clinical Genetics Service & Gastrointestinal Oncology Service

Eytan M. Stein, MD
Chief, Leukemia Service;
Director, Program for Drug Development in Leukemia 

Anna M. Varghese, MD
Assistant Attending Physician, Gastrointestinal Oncology Service

Cy R. Wilkins, MD
Assistant Attending Physician, Hematology Service;
Assistant Professor of Clinical Medicine, Weill Cornell Medical College

Marjorie G. Zauderer, MD
Co-Director MSK Mesothelioma Program; 
Associate Attending Physician, Thoracic Oncology Service

Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics;
Attending Physician, Lymphoma Service

 

Relevant Financial Relationships

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.